FGA139
FGA139 is a cysteine proteases inhibitor with IC50 values of 4.98/3.14 μM for cathepsin B/L. FGA139 reduces LPS-induced NO production in RAW264.7 cells and tumor necrosis factor (TNFα) levels in microglia, and has anti-oxidative stress and anti-inflammatory activities. FGA139 promotes the secretion of neuroprotective metabolites purine and linoleic acid by LPS-stimulated microglia. FGA139 can be used in neuroinflammatory diseases research[1].
Product Specifications
UNSPSC
12352211
Target
Cathepsin; NO Synthase; TNF Receptor
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease
Field of Research
Inflammation/Immunology; Neurological Disease
Smiles
O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC(C)C)C(/C=C/C(OCC)=O)=O)=O)[C@@H](N2N=NC(CCCCC3=C4[N+]([B-](F)(F)N5C3=C(C)C=C5C)=C(C)C=C4C)=C2)CC6=CC=CC=C6
Molecular Formula
C48H58BF2N7O5
Molecular Weight
861.83
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Napsin A (Lung Adenocarcinoma Marker) (NAPSA/1865R), CF405S conjugate, 0.1mg/mL
